Physician profile
Clay A Cauthen
NPI 1730396862
$51,274.23
in general payments reported to CMS, 2019-2025
17 companies · $4,793 in 2025
The $4,793 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $12K · 2021: $8,371 · 2022: $206 · 2024: $31.11 · 2025: $4,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,275 · Travel and Lodging: $1,228 · Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,275.00 |
| Travel and Lodging | $1,228.22 |
| Food and Beverage | $320.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,999.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $19,931.73 | 2019-2024 | |
| Pfizer INC. | $9,829.81 | 2019-2025 | |
| Heartflow, INC. | $249.34 | 2019 | |
| Abiomed | $246.29 | 2019-2021 | |
| Intuitive Surgical, INC. | $186.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $157.36 | 2019-2020 | |
| Medtronic Vascular, INC. | $156.72 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $150.77 | 2019 | |
| Boston Scientific Corporation | $137.58 | 2019-2020 | |
| Bridgebio Pharma, INC. | $111.39 | 2025 | Attruby |
| United Therapeutics Corporation | $57.64 | 2019 | |
| Sandoz INC. | $21.15 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.72 | 2019 | |
| Gilead Sciences, INC. | $18.70 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Cauthen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.